Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA), there has been little progress in developing therapies to ...

Applied Therapeutics, Inc.’s APLT share price has surged by 14.69%, which has investors questioning if this is right time to ...

Detailed price information for Applied Therapeutics Inc (APLT-Q) from The Globe and Mail including charting and trades.

including Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency and PMM2-congenital disorder glycosylation (CDG). To learn more, please visit www.appliedtherapeutics.com. This press ...

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings ...

The decision not to approve the drug was met with consternation by the Galactosemia Foundation, which represents patients with the disorder, and which called the outcome "devastating." There are ...

Gantenerumab for treating early Alzheimer's disease [TSID10668] Technology appraisal guidance Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071] Technology appraisal ...

Current paediatric standard-of-care for galactosemia is a galactose-free diet. Image credit: Shutterstock / Photoongraphy. Nearly three months after an experimental treatment for classic galactosemia ...